A "family" of peptides which produced metabolic or behavioural effects following injections into mice or rabbits had been isolated from the urine from patients with the hypothalamic syndrome congenital, generalized lipodystrophy. Anorexia nervosa is associated with hypothalamic disturbances. Precipitates from urine specimens from 25 patients diagnosed as anorexia nervosa were chromatographed on Sephadex G-25 gel columns, and could be divided into 4 different patterns: One was similar to that for normal controls (4), one similar to that observed for patients with schizophrenia (6), 5 patients with a hysteriform type of neurosis had a third form of pattern, and 10 girls considered to have a primary "hypothalamic" type of anorexia nervosa also had typical chromatograms. Fractions influencing appetite in mice were found in the latter group, only. Two peptides influencing appetite were purified through several steps of chromatography. The sequence of the anorexigenic peptide was verified by the synthesis of the tripeptide, pyroGlu-His-GlyOH. A total dose of 12 nmole of this peptide injected daily over 20 days induced food refusal in mice with reduction of food consumption from 5.7 to about 3 g per day, and the mean body weight decreased from 35 to a minimum of 24.1 g. Food consumption did not normalize until 6 months later, at the same time body weights increased to the same level as in the controls. An appetite stimulating peptide increased the daily consumption of food to more than 10 g, and the mean body weight increased to 57.2 g. We provide evidence for the existence of a hypothalamic form of anorexia nervosa, and that the appetite may be regulated by humoral factors. Screening of peptides present in the urine from patients with anorexia nervosa may give diagnostic and therapeutic information.
There is evidence for neurohumoral control of the endocrine pancreas and appetite (Martin 1978) . Destruction of the ventromedial hypothalamus (Rohner et al. 1977) , or stimulation of the lateral hypothalamus (Parameswaran et al. 1977) induced overeating in rats, probably mediated by increased release of insulin. Stimulation of one rat of a parabiotic pair, inhibited food intake in the other to a point where it stopped eating, lost weight and showed aversion to food. These observations suggested that a substance was released in the fat animal which inhibited the intake of food in the thin animal.
We have previously isolated a crude peptide fraction from urine from patients with congenital generalized lipodystrophy. This fraction produced lipoatrophic diabetes when injected into mice or rabbits (Foss 8c Trygstad 1975) . This state in the animal model was completely reversed by treatment with fenfluramine . The human disease is considered to be the result of deranged hypothalamic function (Seip 1971; Berge et al. 1976 ). We propose that such disorders are the result of transmitter disturbance with hyperfunction of the hypothalamic "gland" leading to overproduction or release of peptides synthesized in hypothalamic neurosecretory neurones, with an overflow to body humours and urine. In vivo studies in duplicate groups of female mice showed refusal of food 4 days after the start of injections of 0.1 mg daily of the heterogenous material in the peak eluting from 600 to 950 ml of pattern A (Fig. 2) (Fig. 1 A) , approximately 3.4 µ of the purified appetite stimulating peptide, and 3.4 «g of the synthetic anorexigenic tripeptide, pyroGlu-His-GlyOH. The purification of the biological anorexigenic factor is to be published (Reichelt et al., subm. for pubi.). The pure factor was characterized as a tripeptide with the structure: L-(pyro)glutamyl-L-histidyl-glycine. The potency had increased 500 times as compared to the initial heterogeneous material, and in¬ duced refusal of food just after the start of the injections (Fig. 2, Table 3 ).
The daily consumption of the chow pellets was reduced from the normal mean of 5.7 g to 2.9 g one week after the start of injections. At Table 3 ). The consumption of food was constantly low. On decapitation, atrophy of the genital organs particularly of the ovaries and the uterus was observed. The mean ovarian weight was reduced from 65 mg for controls to 22 mg.
The synthetic tripeptide pyroGlu-His-GlyOH was observed to produce changes quite similar to those produced by the purified native peptide, although an analogous dose gave a less pronounced refusal of food and decrease in body weight (Fig. 2) . This difference probably is a matter of dosage, due to inaccuracy in the calculation of the dose of the native peptide. After the period of treat¬ ment, the consumption of food varied from 2.9 to 3.9 g per day, and the body weights varied between 24.1 and 26.0 g. However, 7 months after start of treatment the consumption of food and the body weight increased to the normal level. The synthetic peptide produced similar changes in the consumption of oxygen, body temperature and motor activity as observed for the native peptide. These features normalized when the body weight increased.
A peptide producing overeating and development of obesity was obtained from the original crude "anorexigenic" peak (Fig. 2) . The structure of this factor has not yet been determined. A total dose in the range of 10-12 nmole induced a small transitory decrease in food consumption from 5.8 to 4.6 g per day during the period of treatment, and a corresponding decrease in the body weight from 34.8 to 31.1 g. After this period, consumption of chow pellets in-creased and varied between 10.1 to 10.8 g per day 4 months later, compared to 5.7 g for the controls. The mean body weight increased to 57.2 g 7 months after the end of treatment. At decapitation the total body fat contant was 49.8°/o, for control mice it was about 17 %, and 6-7°/o for mice showing food refusal and body weights of 22 g.
Rabbits and pigmented mice were also treated with the anorexigenic peptide and developed food refusal and reduction in weight.
DISCUSSION
A peptide fraction producing lipodystrophy or lipoatrophic diabetes on injection into mice and rabbits, has previously been isolated from urine from patients with congenital generalized lipodystrophy (Foss 8c Trygstad 1975) . We recentlyisolated and characterized three small peptides from the same urine inducing aggression in a stable mouse hierarchy, hyperinsulinaemia in mice (Reichelt et al. 1977) , and an increase in serum testosterone in mice (in press). We have now isolated two peptides from urine from patients considered to have a "hypo¬ thalamic" type of anorexia nervosa. The tripeptide pyroGlu-His-GlyOH which produced food refusal in mice was synthesized and the structure confirmed. The other factor produced overeating and obesity in mice, and is not yet fully characterized. Thus a new system of short chain peptides, which control meta¬ bolic as well as behavioural processes, has been exposed. These The peptide isolated from the urine from patients with "hypothalamic" anorexia nervosa produced refusal of food which persisted for one year in mice, whereas the mice treated with the synthetic peptide reversed to an increase in food consumption and normalization of body weight and temperature 6 months after the period of treatment. It is obvious that the food refusal peptide of human origin suggests itself as a biological anorexigenic agent, and will be further evaluated for its potential use in the treatment of overeating and obesity.
The mechanism of action of the anorexigenic peptide is not established. The atrophy of the genital organs is probably secondary to the refusal to eat. The changes observed in body temperature and activity may suggest a direct effect on the hypothalamic transmitters or on cell receptors with prolonged -chronic inhibition of the lateral feeding centre or a lasting stimulation of the ventromedial satiety area. It has been demonstrated that these areas of the hypotha¬ lamus control insulin and glucagon secretion from the endocrine pancreas (Martin 1978 
